Skip to main content
SpringerLink
Log in

Risk of haemorrhage lower with apixaban than warfarin

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies Thrombosis Research 231: 17-24, 21 Sep 2023. Available from: URL: https://doi.org/10.1016/j.thromres.2023.09.005

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of haemorrhage lower with apixaban than warfarin. Reactions Weekly 1977, 11 (2023). https://doi.org/10.1007/s40278-023-47085-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-47085-6

Search

Navigation